Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability

Sunghoon Kim, Andrew Wolfe, Sung Eun Kim

Research output: Contribution to journalArticlepeer-review


Understanding the mechanisms governing metabolic reprogramming that underlie potential vulnerabilities in cancer cells is key to developing novel therapeutic strategies. The catalytic enzyme UDP-glucose pyrophosphorylase 2 (UGP2) drives the production of UDP-glucose. Our recent work demonstrated the crucial role of UGP2 in cancer growth and its regulation of cellular metabolic processes.

Original languageEnglish
Article number1990676
JournalMolecular and Cellular Oncology
Issue number6
Publication statusPublished - 2021


  • UDP-glucose
  • UGP2
  • YAP
  • cancer metabolism
  • glycosylation

ASJC Scopus subject areas

  • Molecular Medicine
  • Cancer Research


Dive into the research topics of 'Targeting cancer’s sweet spot: UGP2 as a therapeutic vulnerability'. Together they form a unique fingerprint.

Cite this